Numerous studies have explored the efficacy and safety of AODs, including bisphosphonates (Haarhaus et al., 2023), denosumab (Broadwell et al., 2021), and PTH analogs (Bilezikian et al., 2019; Haarhaus et al., 2023; Schroeder et al., 2023), for treating osteoporosis in the general population, postmenopausal women, and patients with different CKD stages. The gene discussed is PTH; the disease is chronic kidney disease.